Should We Perform a New Adjuvant Trial with Bevacizumab?
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Arvind Dasari &Wells A. Messersmith
- چاپ و سال / کشور: 2011
Description
Colorectal cancer is a major cause of cancer-related morbidity and mortality. Complete surgical resection continues to be the mainstay of treatment, followed by adjuvant chemotherapy in all stage III and selected stage II patients. Initial adjuvant clinical trials compared bio-modulated 5- fluorouracil to observation and showed significant improvements in outcomes establishing a role for adjuvant chemotherapy. Experience from subsequent trials suggests that oxaliplatin added to a fluoropyrimidine is the most active combination in the adjuvant setting. In contrast, irinotecan and cetuximab have both failed in the adjuvant setting in spite of proven activity in metastatic disease. Two recent clinical trials provide convincing evidence that bevacizumab also may not improve outcomes in the adjuvant setting. The reasons for these negative results remain unknown. Here, we discuss the results of the adjuvant bevacizumab trials and potential explanations for these findings.
Curr Colorectal Cancer Rep (2011) 7:218–226 DOI 10.1007/s11888-011-0101-6 Published online: 14 June 2011
